血清铁含量检测在酒精性脂肪性肝病和非酒精性脂肪性肝病中的临床意义

目的：探讨铁代谢相关血清学指标在酒精性脂肪性肝病(ALD)和非酒精性脂肪性肝病(NAFLD)中的意义及在肝损伤过程中的作用。方法脂肪性肝病患者406例,其中 ALD 组198例,NAFLD 组208例,另选健康对照组96例,检测血清铁(SF)、铁蛋白(Ferr)及转铁蛋白(TRF)。结果 NAFLD 组、ALD 组 SF、Ferr 水平均高于健康对照组(P <0.05);且 NAFLD 组 SF、Ferr 水平高于 ALD 组。NAFLD 组、ALD 组 TRF 水平均低于健康对照组(P <0.05);且 NAFLD 组 Ferr 水平低于 ALD 组。NAFLD、ALD 组肝硬化亚组血清 SF、Ferr 明显高于肝炎亚组(P <0.05),TRF 明显低于肝炎亚组,差异均有统计学意义(P <0.05)。结论 SF、Ferr 和 TRF 有助于了解脂肪性肝病患者肝损伤程度,特别是对 NAFLD 的预后有重要意义。     

非酒精性脂肪性肝病患者血清瘦素水平与肝脏酶学变化的相关性

目的探讨非酒精性脂肪性肝病患者血清瘦素水平与肝酶学等指标变化的相关性。方法用ELISA法测定血清瘦素水平,结合患者的临床情况及肝脏酶学等指标,采用t检验和相关分析进行数据分析。结果 NAFLD组血清瘦素水平明显高于健康对照组（P〈0.001）;瘦素水平分别与ALT、AST、GGT、TG、FBG、腰臀比、BMI呈正相关,与HDL-C呈负相关;血清瘦素与腰臀比、ALT、FBG呈独立正相关。结论 NAFLD患者血清瘦素水平升高,与肝脏损伤程度及疾病进展有相关性。     

2型糖尿病患者ucOC、CTRP12、CMI指数与非酒精性脂肪性肝病的关系及临床意义

目的 探究2型糖尿病(T2DM)血清羧化不全骨钙素(ucOC)、C1q/肿瘤坏死因子相关蛋白12(CTRP12)、心脏代谢指数(CMI)与非酒精性脂肪性肝病(NAFLD)的关系及临床意义。方法 选取2018年3月至2022年3月该院诊治的T2DM患者152例为研究对象,根据患者是否并发NAFLD分为T2DM组(65例)与T2DM并发NAFLD组(87例)。比较两组患者临床资料、血清ucOC、CTRP12及CMI,采用受试者工作特征(ROC)曲线评估血清ucOC、CTRP12及CMI对T2DM并发NAFLD的预测价值。结果 T2DM并发NAFLD组血清ucOC低于T2DM组(P<0.05),血清CTRP12水平、CMI高于T2DM组(P<0.05)。CTRP12、CMI与TC、TG、LDL-C呈正相关(P<0.05),与HDL-C呈负相关(P<0.05),ucOC与TC、TG、LDL-C呈负相关(P<0.05),与HDL-C呈正相关(P<0.05)。血清ucOC、CTRP12水平及CMI不同分层间,T2DM患者NAFLD的发生率差异均有统计学意义(χ<...     

复方甘草甜素联合左卡尼汀治疗非酒精性脂肪性肝炎

非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)是指病理上与酒精性肝炎相类似但无过量饮酒史的临床综合征,患者通常存在胰岛素抵抗及其相关代谢紊乱。当代谢性肝病的病理学特征不明或泛指整个脂肪性肝病的疾病谱时,通常使用非酒精性脂肪性肝病(NAFLD)这一术语。随着     

非酒精性脂肪性肝病患者血Leptin水平及其相关因素分析

目的　探讨非酒精性脂肪性肝病(NAFLD)患者血Leptin水平及其相关因素。方法　从本院收集 NAFLD的患者50例,其中男性组和女性组各25例,另收集了身体健康男性和女性各25例为对照组,测定体重指 数(BMI),腰臀围比,血空腹胰岛素和Leptin水平。结果　NAFLD两组血Leptin水平均较与之相对应的对照组明 显升高,四组血Leptin水平与BMI(r=0.360,P<0.05)、腰臀围比(r=0.376,P<0.05)和空腹胰岛素(r= 0.334,P<0.05)均呈正相关。女性组血Leptin水平比男性组约高1.5倍(P<0.05)。结论　NAFLD患者血 Leptin水平明显升高,NAFLD患者存在Leptin抵抗。     

血清循环miR-103a-2在非酒精性脂肪性肝病中的表达及意义

目的探讨miR-103作为非侵袭性生物学标志物对非酒精性脂肪性肝病(NAFLD)代谢异常的筛查意义。方法以健康人群和NAFLD患者为研究对象,采集血清样本进行生化指标检测。采用Nucleo ZOL法分离血清miRNA,SYBR Green法对miR-103a-2进行相对定量分析。Speraman法对miR-103a-2和生化指标进行相关性分析。结果血清学分析结果显示,与健康人对照组相比,NAFLD组TC(P0.01)、TG(P0.01)、ALT(P0.01)和γ-GGT(P0.01)水平均明显升高。与血脂正常NAFLD组相比,高脂血症NAFLD组中TC(P0.01)、TG(P0.01)和LDL-C(P0.05)水平均明显升高,与健康人对照组相比,血脂正常NAFLD患者(P0.05)和伴有高血脂症NAFLD患者(P0.01)血清miR-103a-2表达水平均升高。血清miR-103a-2水平与血清TC水平呈正相关(r=0.495,P=0.001)。结论血清miR-103a-2较血脂更为敏感,可能成为NAFLD无创性筛查指标。     

血清瘦素与非酒精性脂肪性肝病及其相关因素分析

目的探讨非酒精性脂肪性肝病患者血清瘦素水平的变化及影响因素。方法将494例非酒精性脂肪性肝病(NAFLD)患者和493例配对的健康对照者纳入研究,采用B型超声对患者进行脂肪性肝病诊断。记录各研究对象基本信息,测量其身高、体重、腰围、臀围和血压,检测空腹血糖(FBG)、总蛋白(TP)、白蛋白(ALB)、球蛋白(GLB)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、尿酸(UA)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)。采用酶联免疫吸附法(ELISA)测定空腹血清瘦素水平。结果①NAFLD患者血清瘦素水平高于健康对照组(P<0.05)。②血清瘦素与HDL-C无显著相关;血清瘦素与年龄、体重、腰围、臀围、FBG、TP、TG、TC、LDL-C、UA、ALT、AST呈显著正相关(P<0.05);与ALB、UA呈显著负相关(P<0.05)。③多元逐步回归分析显示:臀围和LDL-C对瘦素影响最显著,瘦素与臀围和LDL-C呈独立正相关。结论 NAFLD患者血清瘦素水平与健康对照者的血清瘦素水平相比有明显增高。NAFLD患者血清瘦素与LDL-C和臀围密切相关,其可能作为促炎性因子参与了非酒精性脂肪性肝病、动脉硬化性心脑血管疾病及代谢综合征的发病。     

高血压非糖尿病男性患者中非酒精性脂肪性肝病患病率及相关危险因素分析

目的:探讨高血压非糖尿病男性患者中非酒精性脂肪性肝病(NAFLD)的患病率及其相关危险因素。方法:比较按不同体质指数(BMI)、腰臀比(WHR)分组的560例高血压非糖尿病男性患者的NAFLD患病率,并将该560例男性高血压非糖尿病患者按腹部超声检查结果分为NAFLD组(162例)和对照组(398例),观察2组间肝功能及血脂等各项指标的差异;同时应用Logistic逐步回归分析高血压患者中与NAFLD相关的危险因素。结果:高血压非糖尿男性患者中,随着BMI和WHR的升高,其NAFLD患病率明显升高,差异有统计学意义(P<0.05);Logistic逐步回归分析显示,BMI、ALT、LDL-C*载脂蛋B(apoB)是高血压非糖尿病男性患者合并NAFLD的独立危险因素。结论:高血压非糖尿病男性患者中,随着BMI及WHR的增高,NAFLD的患病率也随之上升;BMI、ALT、LDL-C*apoB是高血压非糖尿病男性患者合并NAFLD的独立危险因素。     

非酒精性脂肪性肝病发病时瘦素的变化

目的研究血清瘦素水平在非酒精性脂肪性肝病发病时的变化。方法样本取自2004年10月14日~11月4日在本院体体检中心体检人群,入选标准:BMI25~29.9,无酗酒史,肝炎病毒标志物阴性,无糖尿病者。符合标准的人群共有81例,其中非酒精性脂肪肝患者59例,男40例,女19例;正常对照组22例,男17例,女5例。结果非酒精性脂肪肝病组较对照组BMI更高(26.7 vs 26.15 kg/m2;P=0.02)、WHR(0.9 vs 0.86;P=0.002)及血脂更高(1.99 vs 1.42 mmol/L;P=0.001)、胰岛素敏感指数更低(2.53×10-2vs 3.96×10-2L2*mmoL-1*IU-1;P=0.005),以单因素分析为基础的二值多元lo-gistic回归分析显示:BMI和血脂的影响不存在统计学意义,对非酒精性脂肪肝的发病具有影响的依次是:WHR(P=0.001)和瘦素(P=0.027)。结论在BMI匹配及没有糖尿病的轻度肥胖人群中,瘦素水平在NAFLD组和正常对照之间没有差异,但是多元logistic回归分析显示WHR和瘦素是非酒精性脂肪性肝病发病的独立影响因素。     

脂肪细胞因子在非酒精性脂肪性肝病中的作用

目的：探讨脂肪细胞因子瘦素、脂联素在非酒精性脂肪性肝病发病及其发展中的作用。方法：NAFLD患者60例与健康组60例相对照,ELISA法测定血清瘦素、脂联素水平。结果：NAFLD组与对照组相比,血清瘦素水平明显高于对照组（P〈0.01）,脂联素水平明显低于对照组（P〈0.01）。结论：NAFLD患者血清瘦素水平升高,血清脂联素水平降低,这两种细胞因子均与胰岛素抵抗相关。     

三酰甘油/高密度脂蛋白胆固醇比值对青少年肥胖人群非酒精性脂肪性肝病的预测价值

目的:探讨三酰甘油/高密度脂蛋白胆固醇比值(TG/HDL-C)对肥胖青少年非酒精性脂肪性肝病(NAFLD)的预测价值。方法:选取2012年8月至2017年8月无锡市第二人民医院内分泌科门诊或住院的肥胖青少年患者共114例,收集腰围(WC)、体质指数(BMI)、血压(BP)、氢质子磁共振波普数据(~1H-MRS)、血清谷丙转氨酶(ALT)、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FBG)及胰岛素(INS)等临床指标,计算TG/HDL-C及稳态模型胰岛素抵抗指数(HOMA-IR)。结果:两组患者的年龄、性别、BMI、TC、腰围、舒张压、ALT和空腹血糖及胰岛素差异无统计学意义。高TG/HDL-C组患者收缩压和肝脏三酰甘油含量均显著高于低TG/HDL-C组(P0.05)。多因素Logistic回归分析提示:TG/HDL-C是青少年肥胖人群患NAFLD的独立危险因素(OR=5.78,95%CI 2.23～14.97)。TG/HDL-C预测青少年肥胖人群患NAFLD的ROC曲线下面积为0.73,以2.64为诊断界点时,灵敏度为72.5%,特异度为71.6%。结论:TG/HDL-C有助于预测肥胖青少年人群NAFLD的患病风险。     

三维斑点追踪技术评价2型糖尿病合并非酒精性脂肪性肝病患者左心室功能

目的 探讨三维斑点追踪（3D-STE）技术评估2型糖尿病（T2DM）合并非酒精性脂肪性肝病（NAFLD）患者左心室功能的可行性。方法 对30例T2DM不合并NAFLD（A组）、32例T2DM合并轻度NAFLD（B组）及35例T2DM合并中重度NAFLD患者（C组）行3D-STE检查,检测常规参数,包括二尖瓣口舒张早期与晚期峰值血流速度比值（E/A）、舒张末期室间隔厚度（IVSTd）、左心室下侧壁厚度（PWTd）及舒张末期左心室内径（LVDd）、收缩末期左心室内径（LVDs）,左心室功能参数包括收缩末期左心房容积（LAV）、左心室质量（LVM）、左心室舒张末期容积（LVEDV）、左心室收缩末期容积（LVESV）、左心室质量指数（LVMI）、左心室射血分数（LVEF）,以及3D-STE应变参数左心室整体纵向应变（GLS）、整体面积应变（GAS）、整体径向应变（GRS）和整体圆周应变（GCS）。以Pearson线性相关分析3D-STE参数与糖化血红蛋白（HbA1c）、体质量指数（BMI）的相关性。结果 3组E/A、IVSTd、PWTd、LVDd、LVDs、LVMI、LVEF、LVEDV及LVESV差异均无统计学意义（P均>0.05）,A、B组GRS、GCS、GLS、GAS均较C组增加（P均<0.05）。GLS、GRS、GCS、GAS与HbA1c均呈负相关（r=-0.540、-0.476、-0.489、-0.623,P=0.040、0.032、0.037、0.020）,与BMI均无相关性（P均>0.05）。结论 3D-STE可用于评价T2DM合并NAFLD患者左心室功能。     

2型糖尿病患者血尿酸与非酒精性脂肪肝疾病的相关性

目的探讨2型糖尿病(T2DM)患者中血尿酸(SUA)水平与非酒精性脂肪肝病(NAFLD)的关系。方法对合肥市第一人民医院2010年1月至2016年12月收治的1808例T2DM患者进行横断面研究,通过腹部B超诊断NAFLD,分为非NAFLD组和NAFLD组,其中NAFLD组患者668例,非NAFLD组患者1140例。按照SUA四分位数分为4组(Q1~Q4),分析SUA水平与代谢指标之间的关系。结果本研究人群中NAFLD的发生率为36.9%。Q1、Q2、Q3和Q4四组间年龄、病程、体质指数(BMI)、收缩压(SBP)、舒张压(DBP)、三酰甘油(TG)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨甲酰转移酶(AST)、γ-谷氨酰转肽酶(γ-GT)、血清肌酐(SCr)、空腹血糖(FPG)、空腹C肽(FCP)、高密度脂蛋白胆固醇(HDL-C)、总胆红素(TBIL)差异均具有统计学意义(P<0.05),总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)差异无统计学意义(P>0.05)。在男性中NAFLD的患病率随SUA水平的逐步升高(Q1、Q2、Q3、Q4)逐渐增加(13.07%,32.50%,41.71%,49.75%,P<0.01)。Spearman相关分析显示了SUA与其他代谢指标之间的相关性,在两种性别中SUA水平与BMI、SBP、TG、ALT、AST、γ-GT、SCr、FCP均显著正相关(P<0.01),与FPG、HDL-C、TBIL呈负相关(P<0.01,P<0.05)。多元Logistic回归分析结果显示,BMI、TG、ALT、FCP、SUA是NAFLD的影响因素(P<0.01,P<0.05)。结论T2DM男性患者中SUA与NAFLD密切相关,是NAFLD的独立危险因素。     

非酒精性脂肪肝与血清瘦素和可溶性瘦素受体的关系

目的探讨非酒精性脂肪肝(NAFLD) 发病与患者血清瘦素、可溶性瘦素受体、体重指数(BMI) 及血脂紊乱的关系。方法对96 例经肝穿活检诊断为NAFLD 的患者分为轻、中、重三度, 同时选择20 例肝穿活检正常者为对照, 检测血清瘦素、可溶性瘦素受体水平、空腹血糖、血脂, 测量身高、体质量, 计算BMI。结果NAFLD 组与对照组之间血清瘦素水平、可溶性瘦素受体水平、BMI 及血脂紊乱比较有显著差异( P<0.05 或0.01) 。NAFLD 患者随病变程度加重, 血清瘦素水平有逐渐增高的趋势, 且呈正相关关系(p<0.05),而可溶性瘦素受体水平逐步下降,呈负相关关系(p<0.05)。结论血清瘦素、可溶性瘦素受体、BMI 增高及血脂紊乱是NAFLD 发病的危险因素, NAFLD 病变程度与血清瘦素水平呈正相关,与可溶性瘦素受体水平呈负相关。     

Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: A randomized,controlled trial

ObjectivesThe current study evaluated the effects of green coffee extract (GCE) on serum lipid profile and adiponectin levels in patients with nonalcoholic fatty liver disease (NAFLD).DesignThis randomized, double-blind, placebo-controlled clinical trial was conducted on NAFLD patients aged 20–60 years and body mass index (BMI) of 25−35 kg/m².SettingPatients were recruited from the Bahman poly-clinic (Neyshabur, Iran) between January and June 2016.InterventionsThe study subjects were randomly assigned to receive a daily dose of 400 mg GCE (n = 24) or placebo (n = 24) for eight weeks.Main outcome measuresSerum liver enzyme levels, lipid profile, adiponectin concentrations, and hepatic steatosis grade were measured for all patients at baseline and the end of the trial.ResultsGCE supplementation significantly reduced BMI [mean difference (MD): −0.57 and 95 % confidence interval (CI): −0.84 to −0.29, P < 0.001] and increased serum high-density lipoprotein cholesterol (MD: 7.06, 95 % CI: 0.25–13.87, P < 0.05) compared to the control group. Serum total cholesterol decreased significantly within the GCE group (MD: −13.33, 95 % CI: −26.04 to −0.61, P < 0.05). Triglyceride levels reduced significantly in GCE group compared to the placebo group (MD: -37.91; 95 % CI: −72.03 to −3.80; P = 0.03). However, this reduction was not significant when was further adjusted for mean changes in BMI and daily energy intake (MD: -23.43; 95 % CI: −70.92 to 24.06; P = 0.32). Hepatic steatosis grade, liver enzymes, and adiponectin levels did not show significant differences between the two groups after the intervention.ConclusionsGCE supplementation improved serum lipid profile and BMI in individuals with NAFLD. GCE may be useful in controlling NAFLD risk factors.     

Serum galectin-3 levels in patients with nonalcoholic fatty liver disease

Objectives

Galectin-3 might serve as a biomarker of human metabolic alterations. We measured serum levels of galectin-3 in patients with nonalcoholic fatty liver disease (NAFLD) and examined their association with clinical and histological phenotypes.

Design and methods

Serum levels of galectin-3 were assayed in 71 patients with biopsy-proven NAFLD and 39 controls.

Results

Serum galectin-3 levels did not differ in patients with NAFLD (median 4.1 ng/mL; interquartile range: 1.5–5.5 ng/mL) compared with healthy controls (median 3.1 ng/mL; interquartile range: 0.8–7.5 ng/mL, P = 0.93). Among patients with NAFLD, however, serum galectin-3 levels correlated significantly with BMI (r = 0.267, P < 0.05). This association persisted after adjustment for potential confounders (β = 0.30; t = 2.11, P < 0.05).

Conclusions

Although galectin-3 was modestly associated with BMI, our results do not support the hypothesis that levels of this molecule are altered in patients with NAFLD.     

Effects of lifestyle intervention on soluble CD163, a macrophage activation marker,in patients with non-alcoholic fatty liver disease

Objective: Liver macrophages play an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Soluble CD163 (sCD163), a macrophage-specific biomarker, reflects disease activity in the range of liver diseases. The impact of lifestyle intervention on sCD163 in adult NAFLD patients has not been investigated.

Material and methods: We assessed 126 NAFLD patients participating in a lifestyle intervention study for sCD163 concentrations at baseline, after the three-month intervention period, and at long-term follow-up after 12 and 24?months.

Results: The median sCD163 concentration at baseline was 2.59?mg/L (IQR?=?1.78–3.63?mg/L). There was a significant decrease in sCD163 from baseline to three months follow-up (?0.64?mg/L, p?<?.001) with no difference between the four study groups (p?=?.6). At 12 and 24?months follow-up, the sCD163 concentrations had returned to baseline level (p?=?.3 and p?=?.1). Baseline sCD163 correlated with liver biomarkers and metabolic variables. There was a significantly greater decrease in sCD163 in patients who had a decrease in alanine aminotransferase (ALT) compared with patients with unchanged or increased ALT (?0.76?mg/L vs. ?0.41?mg/L, p?=?.02), and in patients with a decrease in HOMA-IR compared with individuals with no decrease (?0.86?mg/L vs. ?0.55?mg/L, p?=?.03).

Conclusion: sCD163 is associated with markers of liver necro-inflammation and glucose homoeostasis in NAFLD. Participation in a lifestyle intervention programme resulted in a significant reduction in sCD163. Our data support the utility of sCD163 as a biomarker for monitoring the efficacy of therapeutic interventions in NAFLD.     

夜间低氧对慢性阻塞性肺疾病患者血清IL-6、IL-8的影响

目的:探讨慢性阻塞性肺疾病(COPD)患者夜间低氧与全身炎症反应的关系。方法:选择中度至极重度COPD患者70例,年龄45～74岁,平均(65.41±7.84)岁。按多导睡眠监测结果将研究对象分为低氧组和非低氧组,均行肺功能和多导睡眠监测、炎症指标检测。比较各组血清IL-6及IL-8的差异,分析炎症指标与睡眠呼吸参数的相关性。结果:睡眠低氧组27例,低氧率为38.57%,低氧组血清IL-6、IL-8分别为(14.34±2.76) ng/mL、(68.49±9.65) ng/mL,明显高于非低氧组的(11.79±1.85) ng/mL、(61.62±8.47) ng/mL(均P0.001)。经校正年龄、体质量指数后,IL-6与睡眠呼吸相关参数TS88正相关(r=0.651,P=0.041),与最低SaO_2和平均SaO_2负相关(r=-0.644,P=0.038和r=-0.780,P=0.018);IL-8与睡眠呼吸相关参数TS88正相关(r=0.627,P=0.039),与最低SaO_2和平均SaO_2负相关(r=-0.659,P=0.026和r=-0.732,P=0.014)。结论:中度至极重度COPD患者夜间低氧普遍存在,低氧组患者全身炎症反应明显增强,全身炎症反应与夜间低氧相关。     

Effect of soy milk consumption on glycemic status,blood pressure,fibrinogen and malondialdehyde in patients with non-alcoholic fatty liver disease: a randomized controlled trial

ObjectiveDiet plays a critical role in the management of non-alcoholic fatty liver disease (NAFLD). Studies on the NAFLD's experimental models have reported that soy had positive effects on the improvement of metabolic parameters. However, there is a lack of clinical trials regarding the efficacy of whole soy foods. Therefore, this study was conducted to determine the effect of soy milk on some of the metabolic characteristics in patients with NAFLD.MethodsSixty-sex patients diagnosed with NAFLD were included in this randomized, parallel, controlled trial and were randomly assigned to either the soy milk or control group. Both groups received a 500-deficit calorie diet plan. Also, patients in the soy milk group consumed 240 ml/day soy milk for 8 weeks. Fasting blood sugar (FBS), serum insulin, HOMA-IR, HOMA-β%, and QUICKI as well as serum malondialdehyde (MDA), plasma fibrinogen, and blood pressure (BP) were measured at the beginning and end of the study.ResultsAfter 8-weeks of intervention, soy milk group had a greater significant reduction in serum insulin(-3.44 ± 5.02 vs. -1.09 ± 3.77 μIU/ml, P = 0.04), HOMA-IR (-0.45±0.64 vs -0.14 ± 0.47, P = 0.03), systolic (-3.81±4.15 vs -1.48±2.93 mmHg, P = 0.01) and diastolic (-2.39±2.80 vs. -0.94±2.76 mmHg, P = 0.04) BP, and also, a significant increase in QUICKI (0.02± 0.032 vs. 0.008±0.018, P = 0.04) compared to the control group. While, changes in the FBS, HOMA-β%, fibrinogen, and MDA were not significantly different between the study groups.ConclusionA low-calorie diet containing soy milk had beneficial effects on serum insulin, HOMA-IR, QUICKI, and BP in patients with NAFLD.     

Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glucose regulation

Abstract

Background. Dysfunction of adipose tissue is one of the major factors leading to insulin resistance. Altered adipokine concentration is an early sign of adipose tissue dysfunction. The aim of this study was to assess the impact of exercise intervention on adipokine profile, glycemic control, and risk factors of the metabolic syndrome (MeS) in men with impaired glucose regulation (IGR).

Methods. Overweight and obese men with IGR (n =144) aged 40–65 years were studied at baseline and at 12 weeks in a randomized controlled multicenter intervention study. BMI varied from 25.1 to 34.9. The subjects were randomized into one of three groups: 1) a control group (C; n =47), 2) a Nordic walking group (NW; n =48), or 3) a resistance training group (RT; n =49).

Results. Leptin concentrations decreased in the NW group compared to both other groups. Both types of exercise intervention significantly decreased serum chemerin concentrations compared to the C group. In the NW group also body fat percentage, fatty liver index (FLI), and total and LDL cholesterol concentrations decreased compared to the RT group.

Conclusions. Nordic walking intervention seems to decrease chemerin and leptin levels, and subjects in this intervention group achieved the most beneficial effects on components of MeS.